DNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma

International Journal of Medical Sciences

Volumn 10, Issue 12, 2013, Pages 1727-1739

  Khor, Goot Heah ^a,b   Froemming, Gabriele Ruth Anisah ^a   Zain, Rosnah Binti ^b   Thomas Abraham, Mannil ^c   Omar, Effat ^a   Tan, Su Keng ^a   Tan, Aik Choon ^d   Vincent Chong, Vui King ^b   Thong, Kwai Lin ^b  

^a UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^b UNIVERSITY OF MALAYA   (Malaysia)

^c MINISTRY OF HEALTH   (Malaysia)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

DDAH2; DNA methylation profiling; DUSP1; Oral squamous cell carcinoma; Promoter hypermethylation; Protein expression

Indexed keywords

DIMETHYLARGININASE; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE 1; PROTEIN P16;

ADULT; AGE; AGED; ARTICLE; CANCER PROGNOSIS; CHEEK MUCOSA; CLINICAL ARTICLE; CONTROLLED STUDY; DIMETHYLARGININE DIMETHYLAMINO HYDROLASE GENE; DNA METHYLATION; DUAL SPECIFICITY PHOSPHATASE 1 GENE; FEMALE; GINGIVA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIP; MALE; MICROARRAY ANALYSIS; MOUTH SQUAMOUS CELL CARCINOMA; OVERALL SURVIVAL; P16 GENE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; SEX DIFFERENCE; SURVIVAL RATE; TONGUE; TUMOR LOCALIZATION;

DDAH2; DNA METHYLATION PROFILING; DUSP1; ORAL SQUAMOUS CELL CARCINOMA; PROMOTER HYPERMETHYLATION; PROTEIN EXPRESSION.;

ADULT; AGED; AGED, 80 AND OVER; AMIDOHYDROLASES; CARCINOMA, SQUAMOUS CELL; DNA METHYLATION; DUAL SPECIFICITY PHOSPHATASE 1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM PROTEINS; NEOPLASM STAGING; PROMOTER REGIONS, GENETIC; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84885896729     PISSN: 14491907     EISSN: None     Source Type: Journal    
DOI: 10.7150/ijms.6884     Document Type: Article

References (57)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA: a cancer journal for clinicians 2005; 55: 74-108.
2. Jemal A, Bray F, et al. Global cancer statistics. CA: a cancer journal for clinicians 2011; 61: 69-90.
3. Kimman M, Norman R, Jan S et al. The burden of cancer in member countries of the Association of Southeast Asian Nations (ASEAN). Asian Pac J Cancer Prev 2012; 13: 411-420.
4. Kim TJ, Kim HY, Lee KW, Kim MS. Multimodality Assessment of Esophageal Cancer: Preoperative Staging and Monitoring of Response to Therapy. Radiographics 2009; 29: 403-421.
5. Mulero-Navarro S, Esteller M. Epigenetic biomarkers for human cancer: The time is now. Critical Reviews in Oncology/Hematology 2008; 68: 1-11.
6. Balgkouranidou I, Liloglou T, Lianidou ES. Lung cancer epigenetics: emerging biomarkers. Biomarkers in Medicine 2013; 7: 49-58.
7. Liu SA. A Literature Analysis of the Risk Factors for Oral Cancer. Book chapter 2012.
8. Goot-Heah K, Kwai-Lin T, Froemming GRA et al. Human Papilloma Virus 18 Detection in Oral Squamous Cell Carcinoma and Potentially Malignant Lesions Using Saliva Samples. Asian Pacific Journal of Cancer Prevention 2012; 13: 6109-6113.
9. Toyooka S, Maruyama R, Toyooka KO et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. International Journal of Cancer 2002; 103: 153-160.
10. Lin RK, Hsieh YS, Lin P et al. The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 accumulation and tumor suppressor gene hypermethylation in mice and lung cancer patients. The Journal of clinical investigation 2010; 120: 521-532.
11. Maruyama R, Toyooka S, Toyooka KO et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clinical cancer research 2002; 8: 514-519.
12. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nature Reviews Cancer 2006; 6: 107-116.
13. Poage GM, Houseman EA, Christensen BC et al. Global hypomethylation identifies loci targeted for hypermethylation in head and neck cancer. Clinical cancer research 2011; 17: 3579-3589.
14. Ha PK, Califano JA. Promoter methylation and inactivation of tumour-suppressor genes in oral squamous-cell carcinoma. The lancet oncology 2006; 7: 77-82.
15. Khor GH, Froemming GA, Tan AC et al. Pathways Deregulation in Oral Squamous Cell Carcinoma using Methylation Profiling. Journal Dental Research 2011; 91(Special issue C): abs47.
16. Miyamoto K, Ushijima T. Diagnostic and Therapeutic Applications of Epigenetics. Japanese Journal of Clinical Oncology 2005; 35: 293-301.
17. Baylin SB. DNA methylation and gene silencing in cancer. Nature Clinical Practice Oncology 2005; 2: S4-S11.
18. Radhakrishnan R, Kabekkodu S, Satyamoorthy K. DNA hypermethylation as an epigenetic mark for oral cancer diagnosis. Journal of Oral Pathology & Medicine 2011; 40: 665-676.
19. Khor GH, Hassan MI, Siar CH. p53 Expression as a marker of microinvasion in oral squamous cell carcinoma. Asian Pac J Cancer Prev 2011; 12: 1017-1022.
20. Khor GH. Chromosome 17 Aberration of Oral Squamous Cell Carcinoma in Malaysia. Global Jof Health Sci. 2009 2009; 1: 150-156.
21. Shaw R. The epigenetics of oral cancer. International Journal of Oral and Maxillofacial Surgery 2006; 35: 101-108.
22. Ovchinnikov DA, Cooper MA, Pandit P et al. Tumor-suppressor Gene Promoter Hypermethylation in Saliva of Head and Neck Cancer Patients. Translational oncology 2012; 5: 321-326.
23. Buytaert E, Matroule J, Durinck S et al. Molecular effectors and modulators of hypericin-mediated cell death in bladder cancer cells. Oncogene 2007; 27: 1916-1929.
24. Zhang J, Liu J, Li Z et al. Dysfunction of endothelial NO system originated from homocysteine-induced aberrant methylation pattern in promoter region of DDAH2 gene. Chinese Medical Journal 2007; 120: 2132-2137.
25. Galm O, Herman JG. Methylation-specific polymerase chain reaction. Methods Mol Med 2005; 113: 279-291.
26. Gitan RS, Shi H, Chen CM et al. Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis. Genome research 2002; 12: 158-164.
27. Kron K, Pethe V, Briollais L et al. Discovery of novel hypermethylated genes in prostate cancer using genomic CpG island microarrays. PloS one 2009; 4: e4830.
28. Wong IHN. Qualitative and quantitative polymerase chain reaction-based methods for DNA methylation analyses. Methods in Molecular Biology 2006; 336: 33-43.
29. Bibikova M, Barnes B, Tsan C et al. High density DNA methylation array with single CpG site resolution. Genomics 2011; 98:288-295
30. Van Diest P, Van Dam P, Henzen-Logmans S et al. A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Cancer-Gynaecological Cancer Cooperative Group. Journal of clinical pathology 1997; 50: 801-804
31. Shim YH, Kang GH, Ro JY. Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas. Laboratory investigation 2000; 80: 689-695.
32. Klangby U, Okan I, Magnusson KP et al. p16/INK4a and p15/INK4b gene methylation and absence of p16/INK4a mRNA and protein expression in Burkitt's lymphoma. Blood 1998; 91: 1680-1687.
33. Bibikova M, Barnes B, Tsan C et al. High density DNA methylation array with single CpG site resolution. Genomics 2011; 98: 288-295.
34. Olson NE. The microarray data analysis process: from raw data to biological significance. NeuroRx 2006; 3: 373-383.
35. Bibikova M, Le J, Barnes B et al. Genome-wide DNA methylation profiling using Infinium assay. Epigenomics 2009; 1: 177-200.
36. Killian JK, Walker RL, Bilke S et al. Genome-Wide Methylation Profiling in Archival Formalin-Fixed Paraffin-Embedded Tissue Samples. Methods Mol Biol 2012; 823: 107-118.
37. Jithesh P, Risk J, Schache A et al. The epigenetic landscape of oral squamous cell carcinoma. British journal of cancer 2013. 108: 370-379
38. Nazmul-Hossain A, Patel K, Rhodus N, Moser K. Microarrays: applications in dental research. Oral Diseases 2008; 14: 25-29.
39. Rauhala HE, Porkka KP, Tolonen TT et al. Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer. International Journal of Cancer 2005; 117: 738-745.
40. Cao J, Zhou J, Gao Y et al. Methylation of p16 CpG Island Associated with Malignant Progression of Oral Epithelial Dysplasia: A Prospective Cohort Study. Clinical cancer research 2009; 15: 5178-5183.
41. Weber M, Davies JJ, Wittig D et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nature genetics 2005; 37: 853-862.
42. Bibikova M, Lin ZW, Zhou LX et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Research 2006; 16: 383-393.
43. Shaw RJ, Liloglou T, Rogers SN et al. Promoter methylation of P16, RARβ, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. British journal of cancer 2006; 94: 561-568.
44. Sharma G, Mirza S, Prasad CP et al. Promoter hypermethylation of p16 INK4A,p14,ARF,CyclinD2 and Slit2 in serum and tumor DNA from breast cancer patients. Life sciences 2007; 80: 1873-1881.
45. Jablonowski Z, Reszka E, Gromadzińska J et al. Hypermethylation of p16 and DAPK promoter gene regions in patients with non-invasive urinary bladder cancer. Arch Med Sci 2011; 7: 512-516.
46. Ocon E, Becker G, Löning T. p16/MTS1 inactivation in ovarian carcinomas: High frequency of reduced protein expression associated with hyper-methylation or mutation in endometrioid and mucinous tumors. International Journal of Cancer 1998: 61-65.
47. Leiper J, Nandi M. The therapeutic potential of targeting endogenous inhibitors of nitric oxide synthesis. Nature Reviews Drug Discovery 2011; 10: 277-291.
48. Hasegawa K, Wakino S, Tanaka T et al. Dimethylarginine dimethylaminohydrolase 2 increases vascular endothelial growth factor expression through Sp1 transcription factor in endothelial cells. Arteriosclerosis, thrombosis, and vascular biology 2006; 26: 1488-1494.
49. Kim YS, Do JH, Bae S et al. Identification of differentially expressed genes using an annealing control primer system in stage III serous ovarian carcinoma. BMC cancer 2010; 10: 576-590.
50. Korde S, Sridharan G, Gadbail A, Poornima V. Nitric oxide and oral cancer: A review. Oral Oncology 2012; 48: 475-483.
51. Abhary S, Burdon KP, Kuot A et al. Sequence variation in DDAH1 and DDAH2 genes is strongly and additively associated with serum ADMA concentrations in individuals with type 2 diabetes. PLoS One 2010; 5: 1-8
52. Keyse SM. Dual-specificity MAP kinase phosphatases (MKPs) and cancer. Cancer and Metastasis Reviews 2008; 27: 253-261.
53. Calvisi DF, Pinna F, Meloni F et al. Dual-Specificity Phosphatase 1 Ubiquitination in Extracellular Signal-Regulated Kinase-Mediated Control of Growth in Human Hepatocellular Carcinoma. Cancer research 2008; 68: 4192-4200.
54. Uǧurluer G, Ozyurt S, Aksaray F et al. Prognostic factors and survival rates in oral cavity cancers. Journal of ear, nose, and throat 2006; 16: 64-71.
55. Majek O, Gondos A, Jansen L et al. Sex Differences in Colorectal Cancer Survival: Population-Based Analysis of 164,996 Colorectal Cancer Patients in Germany. PLoS One 2013; 8: e68077.
56. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nature reviews genetics 2006; 7: 21-33.
57. Sartor MA, Dolinoy DC, Jones TR et al. Genome-wide methylation and expression differences in HPV (+) and HPV (-) squamous cell carcinoma cell lines are consistent with divergent mechanisms of carcinogenesis. Epigenetics 2011; 6: 777-787.